# Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

> **NCT01252732** · PHASE3 · COMPLETED · sponsor: **Melinta Therapeutics, Inc.** · enrollment: 1019 (actual)

## Conditions studied

- Wound Infection
- Abscess
- Systemic Inflammation
- Cellulitis

## Interventions

- **DRUG:** Single-Dose IV Oritavancin Diphosphate
- **DRUG:** IV Vancomycin

## Key facts

- **NCT ID:** NCT01252732
- **Lead sponsor:** Melinta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 1019 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01252732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01252732, "Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01252732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*